

Product datasheet for TR316993

TAB2 Human shRNA Plasmid Kit (Locus ID 23118)

Product data:

Product Type: shRNA Plasmids

Product Name: TAB2 Human shRNA Plasmid Kit (Locus ID 23118)

Locus ID: 23118

Synonyms: CHTD2; MAP3K7IP2; TAB-2

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection:

Format:

Retroviral plasmids

Components: TAB2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

23118). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

RefSeq: NM 001292034, NM 001292035, NM 015093, NM 145342, NR 125861, NM 015093.1,

NM 015093.2, NM 015093.3, NM 015093.4, NM 015093.5, NM 001292035.1,

NM 001292035.2, NM 001292034.1, NM 001292034.2, BC035910, BC035910.2, BC041998,

BM661637, NM 001369506, NM 001292035.3, NM 001292034.3

UniProt ID: Q9NY|8

Summary: The protein encoded by this gene is an activator of MAP3K7/TAK1, which is required for for

the IL-1 induced activation of nuclear factor kappaB and MAPK8/JNK. This protein forms a kinase complex with TRAF6, MAP3K7 and TAB1, and it thus serves as an adaptor that links MAP3K7 and TRAF6. This protein, along with TAB1 and MAP3K7, also participates in the signal transduction induced by TNFSF11/RANKI through the activation of the receptor activator of NF-kappaB (TNFRSF11A/RANK), which may regulate the development and function of

osteoclasts. Studies of the related mouse protein indicate that it functions to protect against liver damage caused by chemical stressors. Mutations in this gene cause congenital heart defects, multiple types, 2 (CHTD2). Alternative splicing results in multiple transcript variants.

[provided by RefSeq, May 2014]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).